ArticleJournal of inflammation research2025
Dupilumab for Chronic Rhinosinusitis with Primary Nasal Polyps: a Case Report and Literature Review.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To report the efficacy of a case of IL-4 receptor subunit (IL-4Rα) monoclonal antibody (dupilumab) in treating primary chronic rhinosinusitis with nasal polyps (CRSwNP) refractory repeated short-term oral corticosteroids. Patients and Methods: The clinical efficacy, subjective and objective scores, and adverse events before and after dupilumab treatment were evaluated to determine the effect of dupilumab on CRSwNP. Results: The patient's Lund‒Mackay score on sinus Computed Tomography (CT) at the first visit was 21. After being treated with intranasal corticosteroids, oral corticosteroids, mucoregulatory agents, and nasal isotonic saline irrigation for 3 months, the symptoms did not improve significantly. The CT score was 20. The patient explicitly refused functional endoscopic sinus surgery (FESS) and was treated with dupilumab. During treatment, the patient did not experience dupilumab-related adverse reactions, and the patient's sinusitis symptoms were completely controlled. In particular, before dupilumab treatment, the patient lost their sense of smell, with a SNOT-25 score of 65; after the first dose of dupilumab, their sense of smell significantly improved. During the 6-month follow-up, the patient consciously recovered their sense of smell, with a SNOT-25 score of 3. After re-examining the sinus CT image, the Lund-Mackay score was 2. Conclusion: By specifically inhibiting the IL-4 and IL-13 pathways, dupilumab can significantly improve sinusitis symptoms and olfactory function in CRSwNP patients, and significantly reduce the number of acute exacerbations of chronic rhinosinusitis, the range of sinusitis lesions, and the level of systemic corticosteroids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.